Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Molecular Analysis of Samples From Patients With Diffuse Intrinsic Pontine Glioma and Brainstem Glioma

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2014 by Children's Research Institute
Information provided by (Responsible Party):
Javad Nazarian, Children's Research Institute Identifier:
First received: April 19, 2010
Last updated: November 4, 2014
Last verified: November 2014

The purpose of this study is to prospectively collect specimens from pediatric patients with diffuse intrinsic pontine glioma or brainstem glioma, either during therapy or at autopsy, in order to characterize the molecular abnormalities of this tumor.

Diffuse Intrinsic Pontine Glioma
Brainstem Glioma

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Molecular Analysis of Samples From Patients With Diffuse Intrinsic Pontine Glioma and Brainstem Glioma

Resource links provided by NLM:

Further study details as provided by Children's Research Institute:

Primary Outcome Measures:
  • Genome-wide expression patterns of RNA in tumor samples, normal brainstem tissue and cerebrospinal fluid using Affymetrix gene expression profiling [ Time Frame: 4 years ] [ Designated as safety issue: No ]
  • Validation of results of the genome-wide analysis [ Time Frame: 4 years ] [ Designated as safety issue: No ]
  • Proteomic profiling of tumor, normal brainstem tissue and cerebrospinal fluid [ Time Frame: 4 years ] [ Designated as safety issue: No ]
  • Protein expression patterns as assessed by immunohistochemistry and western blot compared to normal brainstem tissue [ Time Frame: 4 years ] [ Designated as safety issue: No ]
  • Genome-wide analysis of tumor samples and normal brainstem tissue [ Time Frame: 4 years ] [ Designated as safety issue: No ]
  • In vitro and in vivo molecular analysis of collected samples [ Time Frame: 4 years ] [ Designated as safety issue: No ]
    Collected samples will potentially be used for in vitro analysis and generation of animal models of this tumor.

Secondary Outcome Measures:
  • Assess aspects associated with specimen acquisition, including potential benefits and drawbacks [ Time Frame: 4 years ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

Cerebrospinal fluid, serum, urine, brainstem tumor and constitutional tissue from patients with diffuse intrinsic pontine glioma or brainstem glioma will be collected.

Estimated Enrollment: 100
Study Start Date: April 2010
Estimated Study Completion Date: April 2020
Estimated Primary Completion Date: April 2016 (Final data collection date for primary outcome measure)
Patient samples
Fresh-frozen and fixed tumor samples, correspondent normal brain tissue samples, cerebrospinal fluid, urine, and serum samples from patients affected with diffuse intrinsic pontine glioma or brainstem glioma

Detailed Description:

High grade diffuse intrinsic pontine glioma (DIPG) accounts for approximately 80% of pediatric brainstem tumors and 10% of pediatric brain tumors, and is the most lethal form of brainstem gliomas in children. There is currently no effective therapy to treat these tumors. We hypothesize that this tumor exhibits unique molecular abnormalities leading to altered RNA and protein expression. The aim of this trial is to collect specimens from pediatric patients with diffuse intrinsic pontine glioma including serum, cerebrospinal fluid, urine, brain tumor and other constitutional tissue, during therapy and/or at autopsy. Our goal is to study this tissue to characterize the genetic abnormalities that lead to tumor formation in order to identify key molecules as biomarkers which we can target to design and test new and more effective treatments.


Ages Eligible for Study:   up to 21 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Community sample


Inclusion Criteria:

  • Patients of any age with clinical and radiologic diagnosis of diffuse intrinsic pontine glioma
  • Patients with other high-grade gliomas originating in the brainstem
  • Patients with focal gliomas (WHO grade I/II) of the brainstem

Exclusion Criteria:

  • Patients with any type of infiltrative low grade (WHO grade I and II) or high grade glioma (WHO grade III and IV) originating outside the brainstem
  • Patients harboring primary brainstem tumors with other histologic diagnoses (e.g., PNET)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01106794

Contact: Javad Nazarian, PhD 202-476-6022
Contact: Madhuri Kambhampati, MS 202-476-5198

United States, District of Columbia
Children's National Medical Center Recruiting
Washington, District of Columbia, United States, 20010
Principal Investigator: Javad Nazarian, PhD         
Sub-Investigator: Roger Packer, MD         
Sub-Investigator: Suresh Magge, MD         
Sub-Investigator: Amanda L Muhs, MD         
Sponsors and Collaborators
Children's Research Institute
Principal Investigator: Javad Nazarian, PhD Children's Research Institute
  More Information

Additional Information:

Responsible Party: Javad Nazarian, Assistant Professor, Children's Research Institute Identifier: NCT01106794     History of Changes
Other Study ID Numbers: DIPG-1
Study First Received: April 19, 2010
Last Updated: November 4, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by Children's Research Institute:
diffuse intrinsic pontine glioma
childhood brainstem glioma
pediatric brainstem glioma
brainstem glioma

Additional relevant MeSH terms:
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neoplasms, Neuroepithelial
Neuroectodermal Tumors processed this record on February 27, 2015